Sopharma AD (BUL: SFA)

Market Cap	991.06M
Revenue (ttm)	1.97B
Net Income (ttm)	77.60M
Shares Out	165.73M
EPS (ttm)	0.49
PE Ratio	12.30
Forward PE	n/a
Dividend	0.99 (16.56%)
Ex-Dividend Date	Jul 11, 2024

Volume	3,558
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	5.58 - 7.76
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. The company operates through Production of Pharmaceutical Products; Distribution of Pharmaceutical Products (Goods); and Others. It offers Carsil to treat liver disease; Tempalgin and Analgin, a painkiller; Tabex, drug used for smoking secession; Tribestan, drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin, used for diseases of the peripheral nervous system; Methylpredni...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 4,721
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2023, Sopharma AD's revenue was 1.89 billion, an increase of 12.95% compared to the previous year's 1.67 billion. Earnings were 95.21 million, an increase of 33.87%.